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A bstract
Hypertensive disorders of pregnancy contribute significantly to maternal mortality and morbidity. Preeclampsia belongs to the
spectrum of hypertensive disorders of pregnancy and if undiagnosed and/or untreated leads to fatal consequences for both the mother
and the baby. Early detection and prevention of preeclampsia is limited by uncertainty in the knowledge about its etiopathogenesis.
While much work has been done in establishing clinical guidelines for management of preeclampsia in the hospital or tertiary care
settings, there is considerable lack of work in the domain of evidence‑based guidelines for screening, identification and management
of preeclampsia at the community‑level. The article reviews these issues with special considerations and to challenges faced in
low and middle‑income countries. There is a need to focus on low‑cost screening and interventions in the community to achieve a
significant impact on preventable maternal and fetal mortality in order to control the burden of preeclampsia significantly as well
as investing on more research at primary care level to improve the evidence base for community‑level interventions.
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of the 21st century, the millennium development goals explicitly
placed maternal health at the core of the struggle against
poverty and inequality.[5] Hypertensive disorders of pregnancy
are an important cause of severe morbidity and mortality among
mothers and infants;[6] and 10% of all women experience it during
pregnancy.[7] Globally, preeclampsia is the second‑leading cause
of maternal mortality, resulting in an estimated 76,000 maternal
deaths annually.[6] In addition, 500,000 fetal and newborn
lives are lost annually due to the perinatal consequences of
preeclampsia.[6] Moreover, preeclampsia complicates 2–8%
of all pregnancies, and 10–15% of direct maternal deaths are
associated with preeclampsia and eclampsia.[7] The syndrome of
hemolysis, elevated liver enzymes and low platelets is a severe
manifestation of preeclampsia and complicates approximately
0.5–0.9% of all pregnancies and 10–20% of cases with severe
preeclampsia.[8] A 20‑fold increase in maternal mortality is
associated with preeclampsia arising at < 32 weeks compared
with that at ≥ 37 weeks.[9] According to a systematic review and
meta‑analysis published in 2007, preeclampsia is associated with
increased risk of having hypertension, ischemic heart disease and

Introduction
Preeclampsia is a condition, within the spectrum of hypertensive
disorders of pregnancy, characterized by elevated blood
pressure and proteinuria, which can progress to involve
multiple organ systems.[1] The Royal College of Obstetricians
and Gynecologists clinically defines preeclampsia as the
presence of pregnancy‑induced hypertension (blood pressure
≥ 140/90 mmHg after 19 weeks of gestation) and significant
proteinuria (>0·3 g/24 h). [2] Preeclampsia can be further
categorized as mild or severe, depending upon the classification
system that is used.[3] Severe preeclampsia includes severe
hypertension (≥170/110 mmHg) and heavy proteinuria, and may
also include other maternal signs of end‑organ dysfunction.[2]
Across the globe, approximately 800 women die due to preventable
causes of pregnancy and childbirth; 99% of these deaths occur
in low and middle‑income countries (LMICs).[4] In the early years
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stroke in later life.[10,11] Overall mortality among women several
years later was also greater in those who had preeclampsia.[10,12]
Preeclampsia is also an important cause of fetal and neonatal
mortality. Hypertension and/or proteinuria during pregnancy
have also been associated with stillbirth[13] while preeclampsia is
strongly associated with fetal growth restriction, low birth weight,
preterm delivery, respiratory distress syndrome, and admission
to neonatal intensive care.[14]

While there are numerous clinical guidelines for diagnosis
and management of preeclampsia in specialist or tertiary care
centers,[20,21] such is not the case for primary care settings in the
community.[2] Preeclampsia community guidelines (PRECOG)
were published in 2005, after having been formulated following
the National Institute for Clinical Excellence’s (NICE)
recommendations for the development of guidelines.[2] This
guideline makes provisions for assessing risk based on evidence,
and gives clear criteria for referral to specialist centers, and also
establishes a schedule for monitoring women in the community
after 20 weeks’ gestation. Criteria of referral for step‑up care
are also given.[2] However, it is important to note that these
guidelines work best only in health systems of developed
nations, and there is a need to contextualize it as per those
of LMICs.

There are a number of hypotheses attempting to explain
the pathogenesis of preeclampsia. The definitive cause of
preeclampsia is generally unknown. Preeclampsia is generally
considered a two‑stage disorder.[15] It is hypothesized that
inadequate trophoblast invasion in early pregnancy results in
impaired placental perfusion, leading to an increase in oxidative
stress. [16] According to one of the hypotheses, impaired
remodeling of the spiral artery is the basis for this stage of the
disease.[17] The later stage of the disease is the development
of systemic endothelial dysfunction, which is responsible for
the characteristic clinical manifestations of preeclampsia.[16]
Underlying metabolic and cardiovascular conditions carry risks
for endothelial dysfunction themselves, which is why they are
postulated to play an important role in the pathogenesis of
late‑onset preeclampsia.[17] It has been proposed that reduced
placental perfection due to oxidative stress causes endothelial
dysfunction, hence linking the two stages of the syndrome.[15]
There is also a genetic association with a multifactorial polygenic
inheritance, suggested to play a role in the development of this
disease.[16]

Perhaps the most important initial step toward a diagnosis of
preeclampsia in community settings is the assessment of risk.
A meta‑analysis by Duckitt and Harrington showed that the
risk of preeclampsia is increased in women with a previous
history of preeclampsia (relative risk 7.19) and in those with
anti‑phospholipids antibodies (relative risk 9.72) and preexisting
diabetes (relative risk 3.56).[22] Patients with multiple pregnancy,
nulliparity, family history, raised body mass index before
pregnancy and maternal age > 40 for multiparous women
were shown to have increased the risk for preeclampsia as
well.[22] A population‑based retrospective study from Canada also
concluded an approximately seven‑fold higher risk of recurrent
severe preeclampsia among women who has severe preeclampsia
in previous pregnancy (6.8%; 95% confidence interval 5.7–
7.9%).[23] Moreover, a history of early‑onset preeclampsia is
associated with increased odds of adverse pregnancy outcomes
despite a normotensive second pregnancy.[24]

Most of the maternal deaths in LMICs occur at the community‑level
where the majority of women do not have access to the health
care facility. Failure to identify preeclampsia along with a delay
in responding to the clinical signs and symptoms is responsible
for nearly half of maternal deaths and more than half of fetal
deaths.[13] In community setups, determining the cause of death
is difficult, and often reliance is placed on the relatives’ or
caretakers’ recall of the symptoms experienced by the women
prior to death.[18] Hence, there is a need for laying the extensive
groundwork in development and implementation of guidelines
and protocols at the community‑level especially in LMICs.
Screening and early detection of preeclampsia in the community
could lead to a decrease in the preventable mortality of mother
and the fetus. Guidelines could be also useful for establishing
thresholds for referral to specialist care, and assessment
procedures for suspected preeclampsia cases.

According to the PRECOG assessment of risk should be
performed before 20 weeks of gestation and women should
be referred for expert evaluation by specialist if they have
either had a previous preeclampsia, a multiple pregnancy,
preexisting underlying medical conditions like renal disease or
chronic hypertension or any two other risk factors from a list.[2]
Complete absence of antenatal care is known to be strongly
associated with fetal death.[25] However, there is no evidence
to recommend special antenatal care in addition to routine, to
women who might be at risk for preeclampsia but otherwise
do not qualify for specialist referral according to PRECOG
criteria.[26] It is possible for women with no risk factors for
preeclampsia to develop the condition. NICE recommends
assessment for preeclampsia at weeks 16, 28, 34, 36, 38,
40, and 41 for healthy parous women with a single fetus.[27]
However, such rigorous schedule of hospital visits might not
be implementable in a LMIC nation where health systems
are overburdened at one end and patients themselves find it
difficult to visit healthcare facilities due to cost and distance
considerations. There is an immense role that community
healthcare workers can play in this arena and future research
should be directed to this issue.

Early Identification and Diagnosis
Prompt diagnosis of preeclampsia in community settings is
necessary to ensure maternal and fetal well‑being. Unlike women
with severe preeclampsia, women with moderate preeclampsia
generally have no symptoms.[7] Therefore, delays in diagnosis,
adequate primary care, and referral to a specialist are likely
to be important contributors of adverse maternal and fetal
outcomes.[19]
Journal of Family Medicine and Primary Care
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Assessments done after 20 weeks’ gestation, by identifying
possible onset of preeclampsia from signs and symptoms
including new hypertension, new proteinuria, symptoms of
headache, visual disturbance, epigastric pain, vomiting, reduced
fetal movements, and an infant that is small for gestational age
can help identifying high‑risk cases for referral to specialist care.[28]
In the community, fetal compromise is usually assessed by asking
women about reduced fetal movements or by assessment for
small for gestational age fetus.[2]

for preeclampsia.[37] Overweight and obese women have an
increased risk for preeclampsia, while underweight women have
an increased risk for preterm delivery.[38] There is some evidence
that secondary prevention with calcium supplementation and
aspirin administration during pregnancy are beneficial in women
with low calcium intake, and at a very high risk of developing
severe early onset disease, respectively.[35]
Anti‑platelet agents, especially low‑dose aspirin, have small‑moderate
benefits when used for prevention of preeclampsia. When
anti‑platelet agents were compared to placebo or no agent, there
was a 17% reduction in the risk of preeclampsia associated with the
use of anti‑platelet agents.[39] There was a small (8%) reduction in
the risk of delivery before 37 completed weeks. Overall there was a
14% reduction in baby deaths in the anti‑platelet group. There was
a 10% reduction in risk of small‑for‑gestational age babies. There
is a need for further research to assess women, which are likely
to benefit most from such interventions and to identify best time
of starting treatment, as well as optimal dosing.[39] A meta‑analysis
that assessed the influence of starting aspirin before 16 weeks
of gestation found a 52% reduction in the risk of preeclampsia
compared with the control group, however no difference was
observed when started after 16 weeks.[40]

The World Health Organization (WHO) antepartum care model
calls for a blood pressure check in the second antenatal visit in
addition to testing for proteinuria in nulliparous women or in
women with previous preeclampsia.[29] The method of measuring
blood pressure is critical: Errors have been implicated in maternal
deaths.[2] Regular maintenance and calibration checks are vital
in ensuring that blood pressure is measured as accurately as
possible. A large of number of devices in use may have an
unacceptable calibration error.[30] The effective management
requires measurement and monitoring of blood pressure.
Low‑cost self‑measurement oscillometric devices, with features
suitable for use in an adult population in a low‑resource setting
in the LMICs, have shown to be acceptable.[31] While both
inflationary and deflationary oscillometry devices are acceptable
for measuring blood pressure, it is possible that inflationary
oscillometry is more accurate for screening for hypertension in
pregnant women with preeclampsia.[32] In conclusion, measuring
blood pressure and proteinuria is challenging in low‑resource
settings due to the financial cost and lack of training. Significant
training is needed to measure blood pressure accurately, along
with the availability of well‑maintained equipment, both of which
pose a challenge to the early identification of preeclampsia in
community settings. A detection tool that is affordable and can
be easily applied is needed.[33]

Calcium supplementation during pregnancy, when compared
with placebo, appears to approximately halve the risk of
preeclampsia.[41] It also reduces the risk of preterm birth and
occurrence of death or serious morbidity.[41] However, it is
of note that existing evidence shows that only women with a
low dietary calcium intake are likely to benefit from calcium
supplementation.[36] Since most pregnant women in LMICs are
deficient in calcium, calcium supplementation is an intervention
of interest for LMICs.[33] Other dietary nutritional measures,
including administration of Vitamin C and other anti‑oxidants,
or drugs have not shown clear, irrefutable benefit, and there is
insufficient evidence to recommend clinical use.[35]

Numerous clinical, biophysical, and biochemical screening tests
have been proposed for the early detection of preeclampsia over
the past decades. However, discrepancies have been reported in
their sensitivity and predictive value. No single screening test used
for preeclampsia prediction has gained widespread acceptance
into clinical practice.[34] It is important to identify at‑risk women
in the community and building the capacity of the caregivers in
community and staff at the primary health centers to manage
women with preeclampsia and eclampsia at the primary care level
itself. Only those that develop complications should be referred
to prevent overburdening of tertiary care facilities.

Management
The goal of managing preeclampsia is to keep blood pressure of
woman in the normal range with anti‑hypertensives and prevent
the development of complications like eclampsia. Delivery of the
fetus and placenta is the only definitive treatment for preeclampsia
but the option, is sadly not available for most patients who are
diagnosed before the baby is full‑term. Treatment is largely
symptomatic with monitoring for development of complications.
Once blood pressure increases above a certain level, it may lead
to direct vascular damage, which in turn leads to life‑threatening
complications such as renal failure, stroke, and fetal distress.[7]
Thus for women with severe preeclampsia, before 34 weeks of
gestation, expectant management is recommended, such that
maternal hypertension is under control, and maternal organ
dysfunction or fetal distress is absent and can be monitored.
However, the evidence‑based behind expectant management for
decreasing neonatal morbidity is small and based on data from
only limited number of trials.[42]

Prevention
The causes of preeclampsia are still largely debatable and mostly
unknown. Hence, it is difficult to formulate strategies for effective
primary prevention at this stage. Research in the past decade
has identified some major risk factors for preeclampsia, and
identification and modification of these factors might result in
a decrease in its frequency.[35,36] Advanced maternal age, obesity,
and no utilization of prenatal care are the risk factors identified
Journal of Family Medicine and Primary Care
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There is no clear drug of choice for use during hypertensive
disorders of pregnancy. In contrast to nonsevere hypertension,
severe hypertension (defined as systolic blood pressure
160 and/or diastolic blood pressure 110) must be treated.
The Confidential Inquiry into Maternal and Child Health
highlighted the importance of treating severe hypertension and
demonstrated that the failure of anti‑hypertensive therapy was
the most common source of sub‑standard care even in high
resource settings.[13] The choice of anti‑hypertensive however is
largely guided by the clinicians experience and familiarity with
a particular drug[43] and on what is known about adverse effects
and teratogenic potential due to lack of good quality evidence
from trials.

addition to the routine clinical tests done and hence might be not
feasible in terms of costs as well as implementation in LMICs.
Furthermore, intervention delivery and targeting the ones at
high risk are a major issue in many LMICs. Despite the existing
proven interventions to prevent and manage preeclampsia and
eclampsia, effective delivery strategies still remain unexplored.
Access to health care, distance, and cost are major obstacles
for women in LMICs to seek care for preeclampsia. Antenatal
care utilization is around 68% in LMICs compared with 98%
in high resource settings.[33] The region of the world with the
lowest levels of use is South Asia, where only 54% of pregnant
women have at least one antenatal care visit.[52] Though the
principles of care for women with preeclampsia remain the
same globally, there is a need to adapt guidelines in the context
of these and other problems unique to LMICs. Delays in
identification, transport, and initiation of treatment because
of number of factors lead to additional health system issues
and this need to be accounted when contextualizing evidence
regarding preeclampsia in LMICs.

The full intravenous or intramuscular regimen of magnesium
sulfate is the drug of choice for both prevention of eclampsia
in severe preeclampsia cases as well as treatment of eclampsia.
In the United Kingdom, widespread uptake of magnesium
sulfate is thought to account for the decline in the incidence
of eclampsia. [44] In LMICs healthcare access is poor and
routine antenatal coverage is not universal or of poor quality
resulting in most patients visiting a clinician at the stage of
severe preeclampsia or eclampsia. Such cases are an obstetric
emergency considering the impending danger to the mother
and the baby. Magnesium sulfate has been found to be
beneficial to use in terms of significantly decreased the risk of
eclampsia (about half) and risk of placental abruption (more than
half) when compared with placebo or no anti‑convulsant.[44,45]
Use of magnesium sulfate in the community is however
limited because of apprehension among healthcare workers
about its safety. This, despite its clear effectiveness, low‑cost,
and being on the essential medicines for most countries, if
not all.[46,47] Toxicity can be monitored clinically by respiratory
rate, urine output and deep tendon reflexes. Limited provider
knowledge and training, and lack of national guidelines and
protocols and sociocultural factors and various other factors
for underutilization of magnesium sulfate has already been
identified.[33,48] For primary care facilities where full schedule
of magnesium sulfate cannot be given or when development
of further complications is anticipated, WHO recommends
giving the loading dose of magnesium followed by referral to
a higher level health‑care facility.[49] Health care worker training
and confidence building measures are hence an important part
of the strategy for controlling the problem of preeclampsia.
Trials comparing alternative regimens of magnesium sulfate
for preeclampsia are of poor quality‑too small and unreliable
for making any conclusions and hence its clinical use not
recommended.[50]

One of the ways forward, especially for the LMICs, could be
scaling up of existing community‑based delivery platforms for
screening and delivering intervention strategies. Many LMICs
have an existing cadre of community health workers (CHWs)
for example Shasthyo Sebikas (Bangladesh), Village Health
Worker (Bhutan), Village Health Guide (India), Female
Community Health Volunteer (Nepal), and Lady Health
Visitor (Pakistan). These existing cadres could be utilized for
screening and early referrals to prevent delays in identification
and treatment. Evidence from Bangladesh, a typical LMIC,
clearly indicates that outcomes were better for community‑based
maternal care programs implemented by posting trained midwives
posted in villages at primary health care system.[53] There are
successful examples from Pakistan where CHWs workers
and midwives have been trained to administer misoprostol in
women with postpartum hemorrhage.[54] This is supportive to
of the recommendation that with proper training, it is feasible
to incorporate even emergency medication administration in
community settings where accessibility and availability are an
issue.
Such an approach is also reasonable as CHWs are already
functioning within the communities to deliver health promotion,
preventive care and essential curative maternal, newborn child
health services. Furthermore, there is a significant amount of
community acceptability of these workers. However, there is
a need to train these CHWs on the concepts related to the
prevention and management of preeclampsia and eclampsia
specifically. There is also a need for focused primary care
funding to evaluate success of such programs before large‑scale
implementation can be done – especially with regard to
conditions like preeclampsia and eclampsia, which turn to
emergencies within a very short span of time. Such efforts thus
need to be supplemented by the development of rapid and
effective emergency care facilities and capacity building of health
facilities where women are being referred to.

Conclusions
Evidence exists that a series of strategies including standardized
assessment and surveillance, adequate management of severe
hypertension, and prevention of eclampsia have the potential
for reducing risks of adverse maternal outcomes in women with
preeclampsia.[51] However, this involves a full detailed work‑up in
Journal of Family Medicine and Primary Care
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It is important to note that there is a need to shift from the current
approach of either ‘vertical’ programs (which only aim at reducing
disease‑specific targets) or “horizontal” programs (which only
aim at solving health system issues and consequently more time
consuming and difficult to implement).[55] For better maternal
and child care it is important to take a “diagonal approach” as
of now and also aim at focused research at primary care level to
improve the evidence base for it.
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